A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis

NDT Plus

Volumn 2, Issue 5, 2009, Pages 347-353

  Bonafont, Xavier ^a   Bock, Andreas ^b   Carter, Dave ^c   Brunkhorst, Reinhard ^d   Carrera, Fernando ^e   Iskedjian, Michael ^f   Molemans, Bart ^c   Dehmel, Bastian ^g   Robbins, Sean ^g  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c AMGEN LTD   (United Kingdom)

^d Klinikum Hannover Oststadt   (Germany)

^e Eurodial   (Portugal)

^f PharmIdeas Research and Consulting Inc   (Canada)

^g AMGEN INC   (United States)

Author keywords

darbepoetin alfa; dialysis; dose savings; epoetin; meta analysis

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; COST CONTROL; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; EMBASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW;

EID: 77956014935     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp097     Document Type: Review

References (30)

1. Kazmi WH, Kausz AT, Khan S et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803-812
2. Anand S, Nissenson AR. Renal anemia management in the chronic kidney disease population. Ann Long Term Care 2002; 10: 43-52
3. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
4. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008; 3: 200-207
5. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
6. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163
7. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446
8. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007; 22(Suppl 4): iv19-iv30
9. Brunkhorst R, Bommer J, Braun J et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004; 19: 1224-1230
10. Hertel J, Locay H, Scarlata D et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Am J Nephrol 2006; 26: 149-156
11. Hertel JE, Locay HR, Scarlata DS et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006; 81: 1188-1194
12. Locatelli F. Once weekly treatment with epoetin-beta. Nephrol Dial Transplant 2005; 20(Suppl 6): vi26-vi30
13. Suranyi MG, Lindberg JS, Navarro J et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-111
14. Bock HA, Hirt-Minkowski P, Brunisholz M et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008; 23: 301-308
15. Molina M, Garćia Herńandez MA, Navarro MJ et al. Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha. Nefrologia 2004; 24: 564-571
16. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
17. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470
18. European Medicines Agency. European Public Assessment Report-Aranesp (22 June) 2008
19. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (Carlton) 2004; 9: 223-228
20. Summers S, Winnott G, Matijevic A. An audit comparing subcutaneous epoetin alfa to intravenous darbepoetin alfa in chronic hemodialysis patients. Dial Transplant 2005; 34: 358-362
21. Shalansky K, Jastrzebski J. Complete switch to darbepoetin in a hemodialysis unit. Clin Nephrol 2005; 64: 55-63
22. Ard̀evol M, Fontseŕe N, Casals M et al. A feasibility cost-analysis study of recombinant human erythropoietin and darbepoetin alfa in ambulatory haemodialysis patients during current clinical practice. Eur J Hosp Pharm Sci 2006; 12: 47-51
23. Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384
24. Mood AM, Graybill FA, Boes D. Introduction to the Theory of Statistics. New York: McGraw-Hill, 1974
25. Icardi A, Sacco P, Salvatore F et al. Long-term intravenous epoetinalpha/ darbepoetin-alpha ratio in iron-replete hemodialysis patients. J Nephrol 2007; 20: 73-79
26. Reḿon C, Quiros P, Ferńandez Marchena D et al. Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa. Nefrologia 2005; 25: 170-177
27. Shaheen FA, Akeel N, Alfi A et al. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia. Saudi J Kidney Dis Transpl 2006; 17: 365-372
28. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583
29. Aarup M, Bryndum J, Dieperink H et al. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006; 21: 1312-1316
30. Cervelli MJ, Gray N, McDonald S et al. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology (Carlton) 2005; 10: 129-135